Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Idorsia in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $20.84.
Current Consensus is
The current consensus among 7 polled investment analysts is to buy stock in Idorsia.
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus. The was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.